Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:59:15.670Z.
Calculation as of: 2026-10-06T19:59:15.670Z.
Quote observation: 2026-10-06T19:55:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8cbf2c4bedb1eff0bddc45c0acac52f2eee77af7ab0e1536e55dbd1c791948ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$3.12B
EBITDA Yield
N/A
TTM Avg
127.06%
3Y Avg
127.06%
5Y Avg
127.06%
Market Cap
$3.06B
EBITDA Yield
N/A
TTM Avg
0.89%
3Y Avg
0.89%
5Y Avg
0.89%
Market Cap
$3.38B
EBITDA Yield
3.21%
TTM Avg
4.14%
3Y Avg
4.45%
5Y Avg
4.45%
Market Cap
$2.99B
EBITDA Yield
1.21%
TTM Avg
0.54%
3Y Avg
0.54%
5Y Avg
0.54%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.20B | N/A | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 127.06% | 127.06% | 127.06% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | 0.53% | 4.11% | 5.67% | 5.67% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 0.89% | 0.89% | 0.89% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 3.21% | 4.14% | 4.45% | 4.45% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.38B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 1.21% | 0.54% | 0.54% | 0.54% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
